These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33421520)

  • 1. Humoral and cell-mediated immune responses to plant-produced African horse sickness virus VP7 quasi-crystals.
    Fearon SH; Dennis SJ; Hitzeroth II; Rybicki EP; Meyers AE
    Virus Res; 2021 Mar; 294():198284. PubMed ID: 33421520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.
    Rutkowska DA; Mokoena NB; Tsekoa TL; Dibakwane VS; O'Kennedy MM
    BMC Vet Res; 2019 Dec; 15(1):432. PubMed ID: 31796116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice.
    O'Kennedy MM; Roth R; Ebersohn K; du Plessis LH; Mamputha S; Rutkowska DA; du Preez I; Verschoor JA; Lemmer Y
    PLoS One; 2024; 19(4):e0301340. PubMed ID: 38625924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge.
    Wade-Evans AM; Pullen L; Hamblin C; O'Hara R; Burroughs JN; Mertens PP
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1611-6. PubMed ID: 9225037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
    Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
    Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
    Crafford JE; Lourens CW; Smit TK; Gardner IA; MacLachlan NJ; Guthrie AJ
    Vaccine; 2014 Jun; 32(29):3611-6. PubMed ID: 24814557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of recombinant African horse sickness virus VP7 antigen via a simple method and validation of a VP7-based indirect ELISA for the detection of group-specific IgG antibodies in horse sera.
    Maree S; Paweska JT
    J Virol Methods; 2005 Apr; 125(1):55-65. PubMed ID: 15737417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants.
    van Rijn PA; Maris-Veldhuis MA; Grobler M; Wright IM; Erasmus BJ; Maartens LH; Potgieter CA
    Vaccine; 2020 Oct; 38(45):7108-7117. PubMed ID: 32921506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
    van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
    Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
    van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
    J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VP7 from African horse sickness virus serotype 9 protects mice against a lethal, heterologous serotype challenge.
    Wade-Evans AM; Pullen L; Hamblin C; O'Hara RS; Burroughs JN; Mertens PP
    Arch Virol Suppl; 1998; 14():211-9. PubMed ID: 9785508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses.
    Dennis SJ; O'Kennedy MM; Rutkowska D; Tsekoa T; Lourens CW; Hitzeroth II; Meyers AE; Rybicki EP
    Vet Res; 2018 Oct; 49(1):105. PubMed ID: 30309390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
    Aksular M; Calvo-Pinilla E; Marín-López A; Ortego J; Chambers AC; King LA; Castillo-Olivares J
    Vaccine; 2018 Nov; 36(46):7003-7010. PubMed ID: 30309744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design.
    Calvo-Pinilla E; Marín-López A; Utrilla-Trigo S; Jiménez-Cabello L; Ortego J
    Curr Opin Virol; 2020 Oct; 44():49-56. PubMed ID: 32659516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.
    Lulla V; Lulla A; Wernike K; Aebischer A; Beer M; Roy P
    J Virol; 2016 Aug; 90(16):7405-7414. PubMed ID: 27279609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
    Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
    Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine.
    Weyer CT; Grewar JD; Burger P; Joone C; Lourens C; MacLachlan NJ; Guthrie AJ
    Vaccine; 2017 Apr; 35(18):2504-2510. PubMed ID: 28341113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.